Bio Green Med Solution AI Stock Analysis
Want to see BGMS full AI Analyst Report?
Bio Green Med Solution (BGMS) AI Stock Analysis
Bio Green Med Solution
(NASDAQ:BGMS)
Bio Green Med Solution (BGMS) achieves an overall score of 50, reflecting a company in transition with mixed fundamentals. The primary risks weighing down the score are a deeply unattractive valuation, persistent negative cash flows, and strong bearish technical momentum as the stock trades below all key moving averages. On the positive side, the company benefits from a clean, zero-debt balance sheet, strong top-line revenue growth, and encouraging corporate developments including reduced net losses and a strategic business pivot.
Bio Green Med Solution (BGMS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.26M
- Dividend Yield
- ―
- Average Volume (3M)
- 73.57K
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 0.88
- Revenue Growth
- 2658.02%
- EPS Growth
- 97.18%
- Country
- US
- Employees
- 12
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Medical - Pharmaceuticals
Bio Green Med Solution Business Overview & Revenue Model
Company Description
Bio Green Med Solution, Inc. (BGMS) operates as a multifaceted company, with active involvement in both the fire protection and biopharmaceutical industries. The organization recently broadened its capabilities by completing the acquisition of Fitter...
Bio Green Med Solution Earnings Call Summary
The earnings call reflects a positive outlook with significant progress in the clinical development of fadra and a strong financial position, despite some challenges in R&D tax credits and increased expenses for topogezotitib.
Q2-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Cyclacel Q2 2024 earnings call, the company provided key updates on their precision medicine strategy, particularly focusing on fadra, an oral CDK2/9 inhibitor. Recruitment is progressing well in the 065-101 Phase II proof-of-concept study, with an enriched cohort targeting patients with CDKN2A and CDK NIB chromosomal abnormalities. Initial clinical activity results are expected in Q4 2024. Financially, Cyclacel reported cash equivalents of $6 million as of June 2024, with net cash used in operating activities amounting to $3.6 million for the first half of the year, indicating a decrease from $8.2 million in the same period of 2023. Research and development expenses for the quarter were $2 million, a reduction from $4.7 million in Q2 2023, with specific R&D expenses for fadra at $1.5 million, down from $3 million the previous year. The company anticipates that current cash resources will cover planned programs into the fourth quarter of 2024.
Bio Green Med Solution Financial Statement Overview
Summary
Demonstrates strong top-line growth and maintains a zero-debt balance sheet, but remains structurally unprofitable with persistent negative cash flows.
Income Statement
55NeutralBalance Sheet
65PositiveCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.23M | 747.00K | 43.00K | 420.00K | 0 | 0 |
| Gross Profit | 458.00K | 138.00K | 43.00K | 420.00K | -32.00K | -43.00K |
| EBITDA | -2.19M | -8.42M | -12.00M | -25.42M | -27.62M | -22.35M |
| Net Income | -1.66M | -3.00M | -11.21M | -22.55M | -21.20M | -18.46M |
Balance Sheet | ||||||
| Total Assets | 7.48M | 8.19M | 4.09M | 8.80M | 28.05M | 43.14M |
| Cash, Cash Equivalents and Short-Term Investments | 3.45M | 3.50M | 3.14M | 3.38M | 18.34M | 36.56M |
| Total Debt | 0 | 2,000 | 0 | 37.00K | 106.00K | 30.00K |
| Total Liabilities | 817.00K | 1.34M | 6.27M | 8.20M | 7.62M | 5.44M |
| Stockholders Equity | 6.66M | 6.84M | -2.17M | 607.00K | 20.43M | 37.69M |
Cash Flow | ||||||
| Free Cash Flow | -951.00K | -4.77M | -7.99M | -16.12M | -20.83M | -18.57M |
| Operating Cash Flow | -950.00K | -4.77M | -7.99M | -16.11M | -20.83M | -18.54M |
| Investing Cash Flow | -1,000 | 0 | 0 | -6,000 | -7,000 | -27.00K |
| Financing Cash Flow | 599.00K | 5.26M | 7.82M | 848.00K | 3.00M | 21.74M |
Bio Green Med Solution Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BGMS, the sentiment is Negative. The current price of 0.59 is below the 20-day moving average (MA) of 0.84, below the 50-day MA of 0.88, and below the 200-day MA of 0.93, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 29.27 is Positive, neither overbought nor oversold. The STOCH value of 10.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BGMS.
Bio Green Med Solution Risk Analysis
Bio Green Med Solution disclosed 63 risk factors in its most recent earnings report. Bio Green Med Solution reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksBio Green Med Solution Peers Comparison
Overall Rating
BGMS50Neutral
NEUP48Neutral
BJDX44Neutral
BDRX40Underperform
RNTX37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| 50Neutral | $3.91M | -0.25 | -24.24% | ― | 2658.02% | 97.18% | |
| 48Neutral | $12.28M | -2.69 | -18.55% | ― | ― | ― | |
| 44Neutral | $2.41M | -0.09 | -113.80% | ― | ― | 95.46% | |
| 40Underperform | $1.12M | -42.39 | -42.42% | ― | ― | 97.97% | |
| 37Underperform | $30.75M | -0.22 | -427.90% | ― | ― | 40.47% |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BGMS | Bio Green Med Solution, Inc. | 0.59 | -0.70 | -54.26% | |
| BDRX | Biodexa Pharmaceuticals Plc | 2.14 | -152.26 | -98.61% | |
| RNTX | Rein Therapeutics, Inc | 0.36 | -0.90 | -71.75% | |
| BJDX | Bluejay Diagnostics, Inc. | 2.15 | -20.56 | -90.51% | |
| NEUP | Neuphoria Therapeutics Inc. | 2.27 | -2.15 | -48.64% |
Bio Green Med Solution Corporate Events
Bio Green Med Solution Declares Quarterly Preferred Dividend
PositiveOn October 15, 2026, Bio Green Med Solution, Inc.’s board declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock. The dividend was scheduled to be paid on November 1, 2026, to preferred shareholders o...
Bio Green Med Solution Reports Improved Q2 2026 Results
PositiveBio Green Med Solution Inc., a Malaysia-headquartered Nasdaq-listed company, has transitioned from its former biopharmaceutical focus to a core business in fire safety protection and equipment distribution since acquiring Fitters Sdn. Bhd. in Septemb...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
